Fibroscan临床应用进展  

New approaches in clinical application of Fibroscan

作　　者：李文庭[1] 高人焘[1] 

机构地区：[1]安徽省立医院感染科,合肥230001

出　　处：《国际流行病学传染病学杂志》2012年第5期344-348,共5页International Journal of Epidemiology and Infectious Disease

基　　金：安徽省青年基金（11040606Q09）

摘　　要：肝脏病理活检是目前评价肝脏病变的金标准，但由于其有创以及阅片者的差异性，限制了肝活检的临床应用。应用Fibroscan测定患者肝脏瞬时弹性（TE）是新近出现的无创、无痛性诊断肝纤维化的方式，由于其安全、可靠、易操作、可重复性好，目前已被广泛应用于各种慢性肝病的诊断、疗效判断以及随访预测。肝脏弹性测定能准确评价慢性肝炎患者肝脏纤维化程度，且与病毒性应答密切相关；能预测门静脉高压、消化道出血、肝癌等终末期肝病并发症等。本文对Fibroscan的临床应用进展及其意义作了综述。Liver biopsy is regarded as the gold standard in liver fibrosis assessment. The invasion and variation among the pathologists limit the application of liver biopsy. However, measurement of transient elastography （TE） by Fi- broscan is a new method to assess liver fibrosis, which is non-invasive, painless. The characteristics of safety, reliability, reproducibility and easy-manipulation make Fibroscan widely used in the diagnosis, curative effect evaluation and follow- up of chronic liver disease. Measurement of TE （also liver stiffness measurement, LSM） is reported to evaluate the degree of liver fibrosis accurately and have a positive correlation with viral response. LSM is also demonstrated to predict the por- tal hypertension, gastrointestinal bleeding, liver cancer and so on. The clinical application and significance of LSM are reviewed in this article.

关 键 词：肝硬化 肝脏弹性 慢性肝病 肝纤维化 

分 类 号：R575.2[医药卫生—消化系统]